Equity Profile

HALO

Halozyme Therapeutics, Inc.

Health CareBiotechnology$11.4B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating profit.

$1.82

Revenue

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

$402M

Wall Street expectations, options signals, track record, and call prep available with Pro.

HALO Q2-2026 Earnings Preview

Context

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases. Operating in the health care sector, Halozyme is known for its proprietary enzyme technology that enhances the delivery of biologic drugs, making it a key player in the evolving biotech landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In the last quarter, Halozyme reported an EPS of $1.60, exceeding expectations by 9.74%. The stock reacted positively, gaining 3.57% the following day.

Management Promises & Guidance

Continued focus on expanding partnerships with major pharmaceutical companies.
Commitment to advancing clinical trials for new therapies.
Plans to enhance production capabilities to meet growing demand.

Expectations

Wall Street Expectations

Analysts expect Halozyme to report solid earnings driven by strong demand for its products. The consensus EPS of $1.82 reflects confidence in the company's growth trajectory.

Bull Case

If Halozyme exceeds EPS expectations and shows robust revenue growth, it could signal strong market demand and solidify its position in the biotech sector.

Bear Case

Conversely, if the company fails to meet EPS or revenue expectations, it may raise concerns about its growth prospects and lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.82

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating profit.

Revenue

$402M

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.82?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction.

What is the revenue outlook compared to the consensus of $402M?

Revenue performance will be critical in assessing the company's growth and market demand.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Halozyme's revenue potential due to recent partnerships that could drive higher sales than anticipated.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% success rate in the last eight quarters.

Recent positive developments in clinical trials may not be fully reflected in current revenue expectations.

Key Risk

If the revenue comes in significantly above $415M, it could challenge the current consensus and shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Halozyme can sustain its growth trajectory amid increasing competition in the biotech sector.

Bull Confirmed If

An EPS of $1.90 or higher would confirm strong profitability and investor confidence.

Bear Confirmed If

An EPS below $1.72 would raise concerns about the company's ability to maintain growth.

Pre-Earnings Positioning

Options Market

Implied Move

±15.76%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±15.8% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

32.9%

Calls (32K)P/C Ratio: 0.10Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests the stock could rise by around 0.49%, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline of approximately 1.31%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on partnerships with pharmaceutical companies and their impact on revenue.
2Details on the progress of ongoing clinical trials and potential new product launches.
3Management's outlook on market demand for their products in the upcoming quarters.
4Any changes in production capabilities to meet growing demand.
5Insights into competitive pressures and how Halozyme plans to address them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating profit.

$1.82

Revenue

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

$402M

Wall Street expectations, options signals, track record, and call prep available with Pro.

HALO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In the last quarter, Halozyme reported an EPS of $1.60, exceeding expectations by 9.74%. The stock reacted positively, gaining 3.57% the following day.

Management Promises & Guidance

Continued focus on expanding partnerships with major pharmaceutical companies.
Commitment to advancing clinical trials for new therapies.
Plans to enhance production capabilities to meet growing demand.

Expectations

Wall Street Expectations

Analysts expect Halozyme to report solid earnings driven by strong demand for its products. The consensus EPS of $1.82 reflects confidence in the company's growth trajectory.

Bull Case

If Halozyme exceeds EPS expectations and shows robust revenue growth, it could signal strong market demand and solidify its position in the biotech sector.

Bear Case

Conversely, if the company fails to meet EPS or revenue expectations, it may raise concerns about its growth prospects and lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.82

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating profit.

Revenue

$402M

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.82?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction.

What is the revenue outlook compared to the consensus of $402M?

Revenue performance will be critical in assessing the company's growth and market demand.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Halozyme's revenue potential due to recent partnerships that could drive higher sales than anticipated.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with an 88% success rate in the last eight quarters.

Recent positive developments in clinical trials may not be fully reflected in current revenue expectations.

Key Risk

If the revenue comes in significantly above $415M, it could challenge the current consensus and shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Halozyme can sustain its growth trajectory amid increasing competition in the biotech sector.

Bull Confirmed If

An EPS of $1.90 or higher would confirm strong profitability and investor confidence.

Bear Confirmed If

An EPS below $1.72 would raise concerns about the company's ability to maintain growth.

Pre-Earnings Positioning

Options Market

Implied Move

±15.76%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±15.8% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

32.9%

Calls (32K)P/C Ratio: 0.10Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests the stock could rise by around 0.49%, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline of approximately 1.31%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on partnerships with pharmaceutical companies and their impact on revenue.
2Details on the progress of ongoing clinical trials and potential new product launches.
3Management's outlook on market demand for their products in the upcoming quarters.
4Any changes in production capabilities to meet growing demand.
5Insights into competitive pressures and how Halozyme plans to address them.